MedPath

Effectiveness of Dextrose Injection for Osgood-Schlatter Disease

Phase 1
Completed
Conditions
Osgood-Schlatter Disease
Interventions
Procedure: Dextrose Injection
Procedure: Lidocaine Injection
Other: Usual Care
Registration Number
NCT01300754
Lead Sponsor
Universidad Nacional de Rosario
Brief Summary

Objective: To examine the potential of dextrose injection versus lidocaine injection versus supervised usual care to change pain/function/activity levels in adolescent athletes with Osgood-Schlatter Disease (OSD).

Detailed Description

Patients and methods: Girls ages 9-15 years old and boys ages 10-17 years old will be assigned to either therapist-supervised usual care, or to double-blind injection of 1% lidocaine solution with or without 12.5% dextrose. Injections will be administered monthly for three months. All subjects will then be offered dextrose injections monthly as needed. Change in the Nirschl Pain Phase Scale (NPPS) will serve as the primary outcome measure.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria
  • Age:9-15 year old girls and 10-17 year old boys
  • Pain Location: Anterior knee.
  • Sport Type: Jumping or kicking sport.
  • Team Member with Coach: Member of and organized team with a coach.
  • Imitation of exact pain and precise location to the tibial tuberosity with a single leg squat.
  • At least 2 months of formal and gently progressive hamstring stretching, quads strengthening, and gradual sports reintroduction.
  • Pain with sport at least 3 months.
Exclusion Criteria
  • Patellofemoral crepitus
  • Patellar origin tenderness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DextroseDextrose Injection-
LidocaineLidocaine Injection-
Usual CareUsual Care-
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hospital Provincial de Rosario

🇦🇷

Rosario, Santa Fe, Argentina

© Copyright 2025. All Rights Reserved by MedPath